Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
122 hedge funds and large institutions have $526M invested in Mersana Therapeutics in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 37 reducing their positions, and 19 closing their positions.
100% more capital invested
Capital invested by funds: $263M → $526M (+$263M)
89% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 19
16% more funds holding
Funds holding: 105 → 122 (+17)
0.12% more ownership
Funds ownership: 3.76% → 3.87% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 37
84% less call options, than puts
Call options by funds: $366K | Put options by funds: $2.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.7M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$6.09M |
| 5 |
JP Morgan Chase
New York
|
+$5.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$24M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$13.7M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$8.44M |
| 4 |
Millennium Management
New York
|
-$7.5M |
| 5 |
Morgan Stanley
New York
|
-$4.74M |
MRSN Hedge Fund Activity: Q1 2024 in Review
122 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q1 2024, worth a combined $526M — up 100% from $263M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MRSN positions and 19 closed out — a net gain of 17 holders — while 33 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $12.6M. The largest seller was Balyasny Asset Management, cutting an estimated $24M.
- 122 institutional investors held Mersana Therapeutics (MRSN) as of Q1 2024, up from 105 in Q4 2023.
- Funds reported $526M of Mersana Therapeutics stock for Q1 2024, up 100% quarter-over-quarter.
- 36 funds opened new Mersana Therapeutics positions in Q1 2024 and 19 closed out, a net change of +17 holders.
- The largest Mersana Therapeutics buyer in Q1 2024 was State Street, an estimated $12.6M added.
- The largest Mersana Therapeutics seller in Q1 2024 was Balyasny Asset Management, an estimated $24M sold.
Based on aggregated 13F filings for Q1 2024.